7 September 2017 - - US-based DNA-based intratumoral cancer immunotherapies developer OncoSec Medical Inc. has appointed Daniel J. O'Connor to its board of directors, the company said.

O'Connor brings more than 20 years of successful financing and licensing experience to OncoSec's board of directors, most recently serving as president and chief executive officer of Advaxis Immunotherapies.

His appointment to the company's board is effective immediately.

Most recently, as president and chief executive officer of Advaxis Immunotherapies, O'Connor successfully turned around the company, raising more than USD 250m in funding and transforming it into a patient-focused, leading cancer immunotherapy company.

He was also instrumental in establishing major partnerships with companies that include Amgen Inc., Merck and Co. and Bristol Myers Squibb.

In addition, under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials, as well as several PD-1 combination clinical studies with Keytruda and Opdivo.

Previously, O'Connor was senior vice president for ImClone Systems where he supported the clinical development, launch, and commercialization of Erbitux, and the sale of the company to Eli Lilly in 2008.

O'Connor served as general counsel at PharmaNet (inventive Health) and was part of the senior leadership team that grew the company from a start-up contract research organisation into a leader in clinical research.

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse, for the treatment of cancer.